Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Gains from Investment Securities (2018 - 2020)

Avai Bio's Gains from Investment Securities history spans 3 years, with the latest figure at -$7203.0 for Q4 2020.

  • On a quarterly basis, Gains from Investment Securities fell 109.6% to -$7203.0 in Q4 2020 year-over-year; TTM through Dec 2020 was -$81864.0, a 209.15% decrease, with the full-year FY2020 number at $320.0, changed N/A from a year prior.
  • Gains from Investment Securities hit -$7203.0 in Q4 2020 for Avai Bio, down from -$461.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AVAI hit a ceiling of $75000.0 in Q4 2019 and a floor of -$74680.0 in Q1 2020.
  • Historically, Gains from Investment Securities has averaged -$858.0 across 3 years, with a median of -$3351.0 in 2018.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 134.7% in 2019 and later crashed 109.6% in 2020.
  • Tracing AVAI's Gains from Investment Securities over 3 years: stood at $31956.0 in 2018, then skyrocketed by 134.7% to $75000.0 in 2019, then crashed by 109.6% to -$7203.0 in 2020.
  • Business Quant data shows Gains from Investment Securities for AVAI at -$7203.0 in Q4 2020, -$461.0 in Q3 2020, and $480.0 in Q2 2020.